Abstract
Platelets play a crucial role in immune responses. Impaired platelet activation may cause persistent mucosal inflammation through P-selectin, CD40-CD40L and other systems influencing granulocytes, macrophages or endothelial cells. Pharmacological regulation of platelet activation may reduce thromboembolism and limit the interaction of platelets with endothelial and inflammatory cells, in turn weakening the inflammatory responses. In this review we focus on pathophysiological activities of platelets in inflammatory bowel diseases and discuss the studies on currently available anti-platelet therapies in the treatment of gastrointestinal inflammation. Finally, we provide a prospective view to new anti-platelet agents currently under development.
Keywords: Anti-platelet agents, inflammatory bowel diseases, platelets, thrombosis.
Current Drug Targets
Title:Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Volume: 16 Issue: 3
Author(s): Chunqiu Chen, Yongyu Li, Zhen Yu, Zhanju Liu, Yanhong Shi, Urszula Lewandowska, Marta Sobczak, Jakub Fichna and Martin Kreis
Affiliation:
Keywords: Anti-platelet agents, inflammatory bowel diseases, platelets, thrombosis.
Abstract: Platelets play a crucial role in immune responses. Impaired platelet activation may cause persistent mucosal inflammation through P-selectin, CD40-CD40L and other systems influencing granulocytes, macrophages or endothelial cells. Pharmacological regulation of platelet activation may reduce thromboembolism and limit the interaction of platelets with endothelial and inflammatory cells, in turn weakening the inflammatory responses. In this review we focus on pathophysiological activities of platelets in inflammatory bowel diseases and discuss the studies on currently available anti-platelet therapies in the treatment of gastrointestinal inflammation. Finally, we provide a prospective view to new anti-platelet agents currently under development.
Export Options
About this article
Cite this article as:
Chen Chunqiu, Li Yongyu, Yu Zhen, Liu Zhanju, Shi Yanhong, Lewandowska Urszula, Sobczak Marta, Fichna Jakub and Kreis Martin, Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases, Current Drug Targets 2015; 16 (3) . https://dx.doi.org/10.2174/1389450116666150113122229
DOI https://dx.doi.org/10.2174/1389450116666150113122229 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Complement and Complement Regulatory Proteins as Potential Molecular Targets for Vascular Diseases
Current Pharmaceutical Design The Emerging Role of Nitrite as an Endogenous Modulator and Therapeutic Agent of Cardiovascular Function
Current Medicinal Chemistry Patent Selections:
Recent Patents on Cardiovascular Drug Discovery The Effect of Local Alcohol Delivery in Reducing Intimal Hyperplasia Induced by Vascular Injury and the Clinical Implications
Vascular Disease Prevention (Discontinued) Autonomic Nervous System Dysfunction in Sjogrens Syndrome
Current Rheumatology Reviews Novel Insights into the Pervasive Role of M3 Muscarinic Receptor in Cardiac Diseases
Current Drug Targets Editors Perspective (Throwing Caution to the Wnts)
Current Neurovascular Research Cardiovascular Disease: A Target for the Pharmacological Effects of Quercetin
Current Topics in Medicinal Chemistry The Cannabinoids Switch of Oxidative Stress: A Double-Edged Sword
Mini-Reviews in Organic Chemistry In Vivo Cellular Imaging for Translational Medical Research
Current Medical Imaging Apoptosis and Acute Brain Ischemia in Ischemic Stroke
Current Vascular Pharmacology Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis
Current Pharmaceutical Biotechnology Angiotensin II and the Cardiac Complications of Diabetes Mellitus
Current Pharmaceutical Design Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery A1 Receptors Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Biotechnological Approaches for the Treatment of Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Psoriasis and Atherosclerosis: Is There a Need For Novel Biomarkers Assessing Cardiovascular Risk?
Current Pharmaceutical Design Clinical Studies with Sirolimus, Zotarolimus, Everolimus and Biolimus A9 Drug- Eluting Stent Systems
Current Pharmaceutical Design Conference Report:
CNS & Neurological Disorders - Drug Targets Mechanisms of Vascular Hyporesponsiveness in Septic Shock
Current Vascular Pharmacology